X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ACTAVIS (US) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ACTAVIS
EQUITY SHARE DATA
    CIPLA
Mar-17
ACTAVIS
Dec-14
CIPLA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs62217,410-   
Low Rs45810,620-   
Sales per share (Unadj.) Rs181.93,135.1-  
Earnings per share (Unadj.) Rs12.9-391.2-  
Cash flow per share (Unadj.) Rs29.3287.6-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.76,799.9-  
Shares outstanding (eoy) m804.51265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.5 66.4%   
Avg P/E ratio x42.0-35.8 -117.1%  
P/CF ratio (eoy) x18.448.7 37.8%  
Price / Book Value ratio x3.52.1 168.3%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5163,726,554 11.7%   
No. of employees `00023.021.6 106.7%   
Total wages/salary Rs m26,3380-   
Avg. sales/employee Rs Th6,349.138,593.4 16.5%   
Avg. wages/employee Rs Th1,143.00-   
Avg. net profit/employee Rs Th449.3-4,816.0 -9.3%   
INCOME DATA
Net Sales Rs m146,302833,617 17.6%  
Other income Rs m2,287-2,081 -109.9%   
Total revenues Rs m148,589831,536 17.9%   
Gross profit Rs m24,758107,090 23.1%  
Depreciation Rs m13,229180,508 7.3%   
Interest Rs m1,59426,294 6.1%   
Profit before tax Rs m12,222-101,793 -12.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-7,467 0.0%   
Tax Rs m1,798-5,233 -34.3%   
Profit after tax Rs m10,354-104,027 -10.0%  
Gross profit margin %16.912.8 131.7%  
Effective tax rate %14.75.1 286.1%   
Net profit margin %7.1-12.5 -56.7%  
BALANCE SHEET DATA
Current assets Rs m87,370439,209 19.9%   
Current liabilities Rs m33,081320,313 10.3%   
Net working cap to sales %37.114.3 260.2%  
Current ratio x2.61.4 192.6%  
Inventory Days Days8758 149.9%  
Debtors Days Days6266 94.0%  
Net fixed assets Rs m111,567101,793 109.6%   
Share capital Rs m1,6090-   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,2541,808,084 6.9%   
Long term debt Rs m36,454947,472 3.8%   
Total assets Rs m209,5323,313,624 6.3%  
Interest coverage x8.7-2.9 -301.9%   
Debt to equity ratio x0.30.5 55.5%  
Sales to assets ratio x0.70.3 277.5%   
Return on assets %5.7-2.3 -243.1%  
Return on equity %8.3-5.8 -143.7%  
Return on capital %8.5-3.0 -282.3%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,824143,148 16.6%  
From Investments Rs m-13,127-342,752 3.8%  
From Financial Activity Rs m-13,239192,577 -6.9%  
Net Cashflow Rs m-2,478-7,027 35.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.82 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: NATCO PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  JUBILANT LIFE SCIENCES  STRIDES SHASUN LTD  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views On News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 23, 2018 01:38 PM

TRACK CIPLA

CIPLA - SUN PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS